Market Overview:
The global cytotoxic drug market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and technological advancements in the field of oncology. Based on type, the global cytotoxic drug market can be segmented into injection, solid oral dose forms, and others. Injection is expected to account for a major share of the global cytotoxic drug market during the forecast period owing to its high efficacy and ease of use. By application, breast cancer is expected to account for a major share of the global cytotoxic drug market during the forecast period owing to its high prevalence across all regions. Other applications include blood cancer, prostate cancer, respiratory/lung cancer, and others.
Product Definition:
Cytotoxic drugs are cancer medications that kill or stop the growth of cancer cells. They work by damaging or destroying the genetic material inside the cells, which prevents them from dividing and growing. Cytotoxic drugs are used to treat a wide variety of cancers, including breast cancer, lung cancer, and ovarian cancer.
Injection:
Injection is a drug form that allows the active ingredients to be absorbed more quickly than a tablet or other oral dosage form. The drug is usually administered by injection into the vein, however some drugs are injectable powder which can be mixed with water or juice and injected as per instructions on the packaging.
The factors responsible for growth of this segment include increasing incidence of cancer globally, rising demand for faster treatment options.
Solid Oral Dose Forms:
Solid oral dose forms are used to deliver cytotoxic drugs. They can be in the form of tablets, capsules, powders or solutions and are manufactured using excipients that help in drug absorption. The most commonly used solid oral dose forms for cytotoxic drugs include Gelsolin (Cytoxan), Alimta (Pamint) and Revlimid (Lenalidomide).
Application Insights:
The breast cancer segment dominated the global cytotoxic drug market in 2017, accounting for over 21.0% share of the overall revenue. Breast cancer is one of the most common types of cancer that affects women during their reproductive years and early adult life span. According to WHO, around 1 in 8 U.S. women develop invasive breast carcinoma at a rate of around 2 per 100,000 every year since 2010 and this number is increasing globally as well as in developed countries like U.S.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, advanced healthcare infrastructure, and high adoption rate for novel therapies are some of the factors responsible for its large share. Moreover, increasing government funding to promote research activities is also expected to drive this regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income and improving healthcare facilities in emerging countries such as China and India. Furthermore, growing awareness about cancer treatment options other than surgery or chemotherapy will propel product demand further over the next eight years.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the cytotoxic drug market. According to the World Health Organization (WHO), in 2012, there were 14 million new cases of cancer and 8.2 million deaths due to cancer worldwide. This number is expected to increase to 21 million new cases and 13 million deaths by 2030. This will create a large demand for cytotoxic drugs, which will drive the growth of this market.
- Rising prevalence of targeted therapies: The rising prevalence of targeted therapies is another major growth driver for the cytotoxic drug market. Targeted therapies are treatments that specifically target tumor cells, while sparing normal cells from damage, thus reducing side effects associated with traditional chemotherapy regimens that affect both tumor and normal cells indiscriminately. As a result, patients are increasingly opting for targeted therapies over traditional chemotherapy regimens, which is driving demand for cytotoxic drugs used in these treatments.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cytotoxic Drug Market Research Report
By Type
Injection, Solid Oral Dose Forms, Others
By Application
Breast Cancer, Blood Cancer, Prostate Cancer, Respiratory/Lung Cancer, Other
By Companies
Roche, Eli Lilly, Celgene, Sanofi, eisai, Sumitomo Dainippon Pharma, Merck, Seattle Genetics, Takeda, Haosoh Pharma, Novartis, AstraZeneca, Jazz Pharma, Spectrum Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Cytotoxic Drug Market Report Segments:
The global Cytotoxic Drug market is segmented on the basis of:
Types
Injection, Solid Oral Dose Forms, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Breast Cancer, Blood Cancer, Prostate Cancer, Respiratory/Lung Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Eli Lilly
- Celgene
- Sanofi
- eisai
- Sumitomo Dainippon Pharma
- Merck
- Seattle Genetics
- Takeda
- Haosoh Pharma
- Novartis
- AstraZeneca
- Jazz Pharma
- Spectrum Pharma
Highlights of The Cytotoxic Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection
- Solid Oral Dose Forms
- Others
- By Application:
- Breast Cancer
- Blood Cancer
- Prostate Cancer
- Respiratory/Lung Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cytotoxic Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A cytotoxic drug is a type of medication that kills cells.
Some of the major companies in the cytotoxic drug market are Roche, Eli Lilly, Celgene, Sanofi, eisai, Sumitomo Dainippon Pharma, Merck, Seattle Genetics, Takeda, Haosoh Pharma, Novartis, AstraZeneca, Jazz Pharma, Spectrum Pharma.
The cytotoxic drug market is expected to grow at a compound annual growth rate of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cytotoxic Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Cytotoxic Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Cytotoxic Drug Market - Supply Chain
4.5. Global Cytotoxic Drug Market Forecast
4.5.1. Cytotoxic Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Cytotoxic Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Cytotoxic Drug Market Absolute $ Opportunity
5. Global Cytotoxic Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Cytotoxic Drug Market Size and Volume Forecast by Type
5.3.1. Injection
5.3.2. Solid Oral Dose Forms
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Cytotoxic Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Cytotoxic Drug Market Size and Volume Forecast by Application
6.3.1. Breast Cancer
6.3.2. Blood Cancer
6.3.3. Prostate Cancer
6.3.4. Respiratory/Lung Cancer
6.3.5. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Cytotoxic Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Cytotoxic Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Cytotoxic Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Cytotoxic Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Cytotoxic Drug Demand Share Forecast, 2019-2029
9. North America Cytotoxic Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Cytotoxic Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Cytotoxic Drug Market Size and Volume Forecast by Application
9.4.1. Breast Cancer
9.4.2. Blood Cancer
9.4.3. Prostate Cancer
9.4.4. Respiratory/Lung Cancer
9.4.5. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Cytotoxic Drug Market Size and Volume Forecast by Type
9.7.1. Injection
9.7.2. Solid Oral Dose Forms
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Cytotoxic Drug Demand Share Forecast, 2019-2029
10. Latin America Cytotoxic Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Cytotoxic Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Cytotoxic Drug Market Size and Volume Forecast by Application
10.4.1. Breast Cancer
10.4.2. Blood Cancer
10.4.3. Prostate Cancer
10.4.4. Respiratory/Lung Cancer
10.4.5. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Cytotoxic Drug Market Size and Volume Forecast by Type
10.7.1. Injection
10.7.2. Solid Oral Dose Forms
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Cytotoxic Drug Demand Share Forecast, 2019-2029
11. Europe Cytotoxic Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Cytotoxic Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Cytotoxic Drug Market Size and Volume Forecast by Application
11.4.1. Breast Cancer
11.4.2. Blood Cancer
11.4.3. Prostate Cancer
11.4.4. Respiratory/Lung Cancer
11.4.5. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Cytotoxic Drug Market Size and Volume Forecast by Type
11.7.1. Injection
11.7.2. Solid Oral Dose Forms
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Cytotoxic Drug Demand Share, 2019-2029
12. Asia Pacific Cytotoxic Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Cytotoxic Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Cytotoxic Drug Market Size and Volume Forecast by Application
12.4.1. Breast Cancer
12.4.2. Blood Cancer
12.4.3. Prostate Cancer
12.4.4. Respiratory/Lung Cancer
12.4.5. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Cytotoxic Drug Market Size and Volume Forecast by Type
12.7.1. Injection
12.7.2. Solid Oral Dose Forms
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Cytotoxic Drug Demand Share, 2019-2029
13. Middle East & Africa Cytotoxic Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Cytotoxic Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Cytotoxic Drug Market Size and Volume Forecast by Application
13.4.1. Breast Cancer
13.4.2. Blood Cancer
13.4.3. Prostate Cancer
13.4.4. Respiratory/Lung Cancer
13.4.5. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Cytotoxic Drug Market Size and Volume Forecast by Type
13.7.1. Injection
13.7.2. Solid Oral Dose Forms
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Cytotoxic Drug Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Cytotoxic Drug Market: Market Share Analysis
14.2. Cytotoxic Drug Distributors and Customers
14.3. Cytotoxic Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Roche
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Eli Lilly
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Celgene
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sanofi
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. eisai
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sumitomo Dainippon Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Merck
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Seattle Genetics
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Takeda
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Haosoh Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Novartis
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. AstraZeneca
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Jazz Pharma
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Spectrum Pharma
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
